Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in Children With Apraxia of Speech
NCT05185583Phase 2Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Mar 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of methylphenidate hydrochloride extended-release chewable tablet in Childhood apraxia of speech (CAS), sponsored by Murdoch Children's Research Institute. Started Mar 2022; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
Childhood apraxia of speech (CAS)
Beyond the preview
Go deeper on NCT05185583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185583.